Literature DB >> 29687465

Diagnostic criteria, severity classification and guidelines of systemic sclerosis.

Yoshihide Asano1, Masatoshi Jinnin2, Yasushi Kawaguchi3, Masataka Kuwana4, Daisuke Goto5, Shinichi Sato1, Kazuhiko Takehara6, Masaru Hatano7, Manabu Fujimoto8, Naoki Mugii9, Hironobu Ihn2.   

Abstract

Several effective drugs have been identified for the treatment of systemic sclerosis (SSc). However, in advanced cases, not only their effectiveness is reduced but they may be also harmful due to their side-effects. Therefore, early diagnosis and early treatment is most important for the treatment of SSc. We established diagnostic criteria for SSc in 2003 and early diagnostic criteria for SSc in 2011, for the purpose of developing evaluation of each organ in SSc. Moreover, in November 2013, the American College of Rheumatology and the European Rheumatology Association jointly developed new diagnostic criteria for increasing their sensitivity and specificity, so we revised our diagnostic criteria and severity classification of SSc. Furthermore, we have revised the clinical guideline based on the newest evidence. In particular, the clinical guideline was established by clinical questions based on evidence-based medicine according to the New Minds Clinical Practice Guideline Creation Manual (version 1.0). We aimed to make the guideline easy to use and reliable based on the newest evidence, and to present guidance as specific as possible for various clinical problems in treatment of SSc.
© 2018 Japanese Dermatological Association.

Entities:  

Keywords:  diagnostic criteria; guidelines; severity classification; systemic sclerosis; treatment

Mesh:

Substances:

Year:  2018        PMID: 29687465     DOI: 10.1111/1346-8138.14162

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  7 in total

1.  [Expression of pituitary tumor-transforming gene-1 and its pathogenic role in systemic sclerosis].

Authors:  Anqiao Yang; Yan Huang; Yuting Zhang; Kai Yang; Jiucun Wang; Qingmei Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-11-30

2.  Lymphocyte proliferation induced by high-affinity peptides for HLA-B*51:01 in Behçet's uveitis.

Authors:  Toshikatsu Kaburaki; Hisae Nakahara; Rie Tanaka; Kimiko Okinaga; Hidetoshi Kawashima; Youichiro Hamasaki; Thanyada Rungrotmongkol; Supot Hannongbua; Hiroshi Noguchi; Makoto Aihara; Fujio Takeuchi
Journal:  PLoS One       Date:  2019-09-12       Impact factor: 3.240

Review 3.  Classical Disease-Specific Autoantibodies in Systemic Sclerosis: Clinical Features, Gene Susceptibility, and Disease Stratification.

Authors:  Changyi Yang; Shunli Tang; Dingxian Zhu; Yingguo Ding; Jianjun Qiao
Journal:  Front Med (Lausanne)       Date:  2020-11-19

Review 4.  Esophageal Dysfunction in Systemic Sclerosis: An Update.

Authors:  Bo Li; Junqing Yan; Jincheng Pu; Jianping Tang; Shuchang Xu; Xuan Wang
Journal:  Rheumatol Ther       Date:  2021-10-09

Review 5.  Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases.

Authors:  Masanori Ono; Kimikazu Matsumoto; Narikazu Boku; Nobuharu Fujii; Yumi Tsuchida; Tatsuro Furui; Miyuki Harada; Yoshinobu Kanda; Akira Kawai; Mitsuru Miyachi; Atsuko Murashima; Robert Nakayama; Hiroyuki Nishiyama; Chikako Shimizu; Kazuhiko Sugiyama; Yasushi Takai; Keishi Fujio; Ken-Ichirou Morishige; Yutaka Osuga; Nao Suzuki
Journal:  Int J Clin Oncol       Date:  2021-11-17       Impact factor: 3.402

6.  Development of End Stage Renal Disease after Long-Term Ingestion of Chaga Mushroom: Case Report and Review of Literature.

Authors:  Sua Lee; Hwa Young Lee; Yohan Park; Eun Jeong Ko; Tae Hyun Ban; Byung Ha Chung; Hyun Soon Lee; Chul Woo Yang
Journal:  J Korean Med Sci       Date:  2020-05-18       Impact factor: 2.153

7.  Hyaluronic acid and platelet-rich plasma, a new therapeutic alternative for scleroderma patients: a prospective open-label study.

Authors:  Roberto Pirrello; Barbara Verro; Giulia Grasso; Piero Ruscitti; Adriana Cordova; Roberto Giacomelli; Francesco Ciccia; Giuliana Guggino
Journal:  Arthritis Res Ther       Date:  2019-12-13       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.